

SUPPLEMENTARY APPENDIX

Activation-induced markers (AIM) T cell assay.....	1
List of Reagents.....	2
Figure S1.....	3
Table S1. Demographic data of the study's participants.....	7
Table S2. Antibodies and fluorochromes used in the activation induced marker (AIM) assay.....	8
Table S3. Statistical differences on IgG levels against wild-type SARS-CoV-2 and SARS-CoV-2 variants of concern (VOCs)	9

Activation-induced markers (AIM) T cell assay - full protocol

PBMCs were thawed at 37°C and diluted in RPMI 1640 media (Thermo Scientific, MA, USA) supplemented with 5% human serum (Sigma-Aldrich, Darmstadt, Germany), 2 mM L-glutamine (Gibco, MA, USA), 1 mM penicillin/streptomycin (Gibco, MA, USA), 10 mM HEPES solution (Gibco, MA, USA), 1mM sodium pyruvate (Gibco, MA, USA) and 55 mM β-mercaptoethanol (Gibco, MA, USA) (hereafter referred as HR5). Cells were centrifuged at 1500 rpm for 10 min, resuspended in HR5 containing 50 U/mL benzonase (Merck, Darmstadt, Germany) and incubated at 37°C and 5% CO₂ to remove DNA/RNA aggregates. After incubation, cells were counted, centrifuged at 1500 rpm for 10 min and seeded at a density of 1,5x10⁶ cells per well, in U-bottom 96-well plates.


Cells were incubated with 0,5 µg/mL anti-CD40 antibody (Miltenyi Biotec, NRW, Germany) for 15 min at 37°C and 5% CO₂ and then stimulated for 24h at 37°C and 5% CO₂ in the presence of specific MPs (1 µg/mL), phytohemagglutinin (PHA, Sigma-Aldrich, Darmstadt, Germany) (10 µL/mL) as a positive control or dimethyl sulfoxide (DMSO, Sigma-Aldrich, Darmstadt, Germany) (0,1 %) as a negative control, all diluted in HR5. MPs were developed and kindly donated by Dr. Alessandro Sette's laboratory (Center for Infectious Disease and Vaccine Research; La Jolla Institute for Immunology, USA) (Grifoni et al., 2020) and comprehend SARS-CoV-2-specific epitopes specified as CD4-R (remaining non-Spike protein), CD4-S (Spike protein) and CD8-A and CD8-B (viral epitopes compatible with HLA-A and HLA-B, respectively).

After a 24-hours MPs incubation, plates were centrifuged at 1800 rpm for 2 min and the supernatant was collected in a new plate and kept at -80°C freezer for further analysis. Cell pellets were resuspended, transferred to V-bottom 96-well plates and washed with MACS buffer (5 mg/mL bovine serum albumin (BSA, Sigma-Aldrich, Darmstadt, Germany) and 2 mM ethylenediamine tetraacetic acid (EDTA, Sigma-Aldrich, Darmstadt, Germany) diluted in phosphate-buffered saline 1X (PBS, LGC Biotechnologia, SP, Brazil)) twice, then stained with a specific antibodies mix containing characterization and activation markers (Supplementary Appendix) for 20 min, at 4°C in the dark (Moderbacher et al., 2020). After staining, cells were washed twice at the same conditions, fixed with paraformaldehyde (PFA, Sigma-Aldrich, Darmstadt, Germany), diluted 1:10 in PBS 1X, for 10 min at room temperature in the dark, centrifuged at 2000 rpm for 5 min, resuspended in PBS 1X and acquired at the BD LSRFortessa™ X-20 Cell Analyzer (BD Biosciences, CA, USA).


List of Reagents

1. RPMI 1640 media (Thermo Scientific, MA, USA)
2. 5% human serum (Sigma-Aldrich, Darmstadt, Germany)
3. 2 mM L-glutamine (Gibco, MA, USA)
4. 1 mM penicillin/streptomycin (Gibco, MA, USA)
5. 10 mM HEPES solution (Gibco, MA, USA)
6. 1mM sodium pyruvate (Gibco, MA, USA)
7. 55 mM β -mercaptoethanol (Gibco, MA, USA)
8. 50 U/mL benzonase (Merck, Darmstadt, Germany)
9. Specific SARS-CoV-2 megapools (Center for Infectious Disease and Vaccine Research; La Jolla Institute for Immunology)
10. anti-CD40 antibody (Miltenyi Biotec, NRW, Germany)
11. Phytohemagglutinin (PHA, Sigma-Aldrich, Darmstadt, Germany)
12. Dimethyl sulfoxide) (DMSO, Sigma-Aldrich, Darmstadt, Germany)
13. U-bottom 96-well culture plates (TPP, Trasadingen, Switzerland)
14. MACS buffer:
 - 5 mg/mL bovine serum albumin (BSA, Sigma-Aldrich, Darmstadt, Germany)
 - 2 mM ethylenediamine tetraacetic acid (EDTA, Sigma-Aldrich, Darmstadt, Germany)
 - phosphate-buffered saline 1X (PBS, LGC Biotecnologia, SP, Brazil)
15. Paraformaldehyde (PFA, Sigma-Aldrich, Darmstadt, Germany), diluted 1:10 in PBS 1X
16. V-bottom 96-well plates (NUNC, Thermo Scientific, MA, USA)
17. V-PLEX SARS-CoV-2 Panel 7 IgG kit, catalogue number K15437U-4 (MesoScale Discovery, MD, USA)


A







B



C



D**E**



F





Figure S1. Specific wt and VOCs SARS-CoV-2 strains IgG titers through one-year follow-up.

Graphs show anti-SARS-CoV-2 IgG levels in AU/mL from vaccinees throughout one year, and placebos and infected patients as controls. Symbol colours represent age-groups (black: 18-59, grey: ≥ 60). Symbol shapes represent different volunteer sub-groups (unfilled circle: placebos (n=8), filled circle: vaccinees (n=53), filled triangles: SARS-CoV-2 infected hospitalized 19 days of symptoms onset (median, 17-22 days IQR) (n=6) or non-hospitalized individuals, 46 days of symptoms onset (median, 34-65 days IQR) (n=6)). 0d: vaccinee baseline, day of first vaccine dose. 14d: two-weeks after the first dose, day of the second vaccine dose. Mann-Whitney test was performed to compare both age groups in each visit, and asterisks indicate a statistically significant difference according to the p-value: * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. IgG levels were measured for (A) wild-type Spike protein; (B) wild-type RBD protein; (C) wild-type nucleocapsid protein; (D) Alpha Spike and RBD proteins; (E) Beta Spike and RBD proteins and (F) Gamma Spike and RBD proteins.

Table S1. Demographic data of the study's participants.

Groups	Age*	Sex	Days between vaccine doses*	Days of symptoms onset*	COVID-19 Diagnosis
<i>Placebo (n=8)</i>	54 (36-64)	62.5% F 37.5% M	-	-	-
<i>Vaccinees</i>					
18-59 (n=29)	36 (31-42)	55.2% F 44.8% M	15 (14-18)	-	-
≥60 (n=24)	67 (63-70)	33.3% F 66.7% M	16 (14-21)	-	-
<i>COVID-19 infected individuals</i>					
<i>Hospitalized (n=8)</i>	53 (43-62)	12.5% F 87.5% M	-	19 (17-22)	75% PCR 25% Sorology
<i>Non-Hospitalized (n=9)</i>	40 (33-44)	55.6% F 44.4% M	-	46 (34-65)	100% PCR

Table S2. Antibodies and fluorochromes used in the activation induced marker (AIM) assay.

Fluorochrome	AIM T CD4⁺ cells	AIM T CD8⁺ cells
BB515	CD3 (UCHT1)	CD3 (UCHT1)
APC-H7	CD4 (RPA-T4)	CD4 (RPA-T4)
PerCP CY5,5	CD8 (SK1)	CD8 (SK1)
BV786	PD1 (EH12.1)	-
APC	CD45RA (HI100)	CD45RA (HI100)
PE-CY7	CD25 (M-A251)	-
BV711	CXCR3 (1C6)	CXCR3(1C6)
BV421	CCR7 (G043H7)	CCR7 (G043H7)
Alexa Fluor 700	CD40/CD154 (24-31)	-
APC-R700	-	CD38 (HIT2)
BV510	CD137 (4B4-1)	CD137 (4B4-1)
BV605	CXCR5 (RF8B2)	-
PE	OX40 (Ber-ACT35)*	CD69 (FN50)
PE-CF594	Live-Dead**	Live-Dead**

*All antibodies were acquired from BD Biosciences, excepting from anti-OX40 (Biolegend). Clones were described in parenthesis. **Cell viability marker, Live/Dead, CF-594, Life Technologies.

Table S3. Statistical differences on IgG levels (AU/ml) against SARS-CoV-2 wt and variants of concern (VOCs), Alpha, Beta and Gamma. First line of each protein target represents statistical differences between each age group (18-59 or ≥ 60) with respective baseline (0d) measures, and the second line represents statistical differences between both age groups (18-59 and ≥ 60).

	0d		14d		28d		42d		90d		180d		270d		365d	
	18-59	≥ 60	18-59	≥ 60	18-59	≥ 60	18-59	≥ 60	18-59	≥ 60	18-59	≥ 60	18-59	≥ 60	18-59	≥ 60
N	-	-	>0,9999	>0,9999	<0,0001	0,0756	<0,0001	0,0412	<0,0001	0,0088	0,0159	0,0383	0,1902	0,8948	0,1004	>0,9999
	0,1675		0,0101		0,0003		<0,0001		0,0002		0,0562		0,1061		0,1984	
wt Spike	-	-	0,0004	0,2999	<0,0001	<0,0001	<0,0001	<0,0001	<0,0001	<0,0001	<0,0001	<0,0001	0,0090	0,0012	0,0010	0,1182
	0,5979		0,0002		0,0047		0,0157		0,4208		0,5239		0,5177		0,2404	
wt RBD	-	-	0,0015	0,3331	<0,0001	<0,0001	<0,0001	<0,0001	<0,0001	<0,0001	<0,0001	<0,0001	0,0043	0,0070	0,0008	0,1448
	0,1102		0,0007		0,0095		0,0211		0,5463		>0,9999		0,1816		0,4980	
α Spike	-	-	0,0002	0,2779	<0,0001	<0,0001	<0,0001	<0,0001	<0,0001	<0,0001	<0,0001	<0,0001	0,0068	0,0074	0,0008	0,1919
	0,7032		0,0004		0,0077		0,0211		0,4533		0,3155		0,1598		0,1455	
α RBD	-	-	0,0018	0,3720	<0,0001	<0,0001	<0,0001	<0,0001	<0,0001	<0,0001	<0,0001	<0,0001	0,0022	0,0037	0,0008	0,1343
	0,0188		0,0002		0,0047		0,0188		0,3600		0,8455		0,1705		0,3998	
β Spike	-	-	0,0003	0,1816	<0,0001	<0,0001	<0,0001	<0,0001	<0,0001	<0,0001	<0,0001	<0,0001	0,0198	0,0043	0,0019	0,2120
	0,7396		0,0003		0,0067		0,0072		0,2964		0,1615		0,1816		0,1164	
β RBD	-	-	0,0165	0,5523	<0,0001	<0,0001	<0,0001	<0,0001	<0,0001	<0,0001	<0,0001	<0,0001	0,0253	0,0038	0,0009	0,3004
	0,0880		0,0023		0,0037		0,0051		0,3897		0,6306		0,2604		0,3698	
γ Spike	-	-	0,0002	0,1953	<0,0001	<0,0001	<0,0001	<0,0001	<0,0001	<0,0001	<0,0001	<0,0001	0,0083	0,0003	0,0011	0,0854
	0,3795		0,0002		0,0150		0,0298		0,4315		0,5585		0,7857		0,1036	
γ RBD	-	-	0,0025	0,3257	<0,0001	<0,0001	<0,0001	<0,0001	<0,0001	<0,0001	<0,0001	<0,0001	0,0205	0,0033	0,0005	0,1286
	0,0131		0,0002		0,0034		0,0044		0,2558		0,9689		0,2171		0,464	

Colours represent statistical difference according to p-value, being grey: no significant, light yellow: * $p < 0.05$, light orange: ** $p < 0.01$, light red: *** $p < 0.001$ and red: **** $p < 0.0001$.